Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Date:4/15/2008

- 80% of Subjects Immunized with Anti-PS Immunocytokines and Irradiated Tumor Cells Achieved Long-Term Survival Compared to Just 20% of Controls -

- Data Highlights Broad Anti-Cancer Potential of Peregrine's Anti-PS

Vascular Targeting Antibodies -

SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that a preclinical study presented yesterday at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) demonstrates the vaccine-like ability of immunocytokine proteins combining its anti-phosphatidylserine (anti-PS) antibodies and cytokines such as IL-2 to generate robust and protective immune responses in a highly aggressive cancer model. Dr. Xianming Huang, assistant professor of pharmacology, and colleagues at the University of Texas Southwestern Medical Center at Dallas presented their findings from a study in mice assessing the efficacy of a tumor vaccine approach that uses these anti-PS immunocytokines in combination with radiation to achieve immunity to a lethal form of breast cancer.

Dr. Huang commented, "A likely contributor to the lack of immunogenicity of tumors is the fact that phosphatidylserine (PS) expressed on the surface of some cancer cells acts to dampen the body's normal immune response. By coating cancer cells with our anti-PS immunocytokines and then irradiating them to up-regulate the expression of the PS target, we were able to block the immunosuppressive effect of the PS. This enabled the pre-treated animals to leverage the T-cell activating effects of the IL-2 in the immunocytokine to mount a robust and sustained immune response to this unusually aggressive cancer."

In the study
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
7. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
8. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... June 19, 2013 DST Health Solutions, LLC ... to health plans, integrated delivery systems, and health care ... Drug Management Service (MDMS) has jumped significantly. ... automate the pricing of medical prescription drug claims, MDMS ... automating their medical drug claims processes. As specialty drug ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3
... 27 ChemoCentryx, Inc., today announced that ... PROTECT-1 Study (the Prospective Randomized Oral Therapy ... (CCX282-B) in patients with moderate-to-severe Crohn,s disease. ... antagonist showed clinical efficacy in a 12-week ...
... NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... specializing in the development, manufacturing, and marketing of branded ... it will report its unaudited financial results for the ... 11, 2010, before the market opens in the United ...
Cached Medicine Technology:ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 2ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 3ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 4ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 5Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010 2
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... ROCHESTER, Minn. -- Nearly 70 percent of ... and more than half take two, Mayo Clinic ... most commonly prescribed, their study found. Twenty percent ... medications, according to the findings, published online in ... MULTIMEDIA ALERT: For audio and video of Dr. ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... More than 90% of drugs entering,clinical development fail ... of,effectiveness or adverse side effects not detected in ... pre-clinical tests using stem cell,technologies, potentially saving drug ... Cells: Worldwide Markets for,Transplantation, Cord Blood Banking and ...
... condition associated with pregnancy responds to energy restoration, ... the editor,in today,s USA Today, board-certified cardiologist Stephen T. ... a rare and often,misunderstood form of heart disease. Responding ... twins who developed peripartum cardiomyopathy, an,uncommon and mystifying type ...
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. ... the BioCentury "Future,Leaders in the Biotech Industry" Conference ... New York City on Thursday, March 27, 2008 ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... GlaxoSmithKline (NYSE: GSK ),today reported its ... equivalent to almost 4% of pre-tax profits for ... Donations of albendazole treatments,for the company,s flagship program ... valued at $29 million, bringing the,total number of ...
... of natural compound found in heparin samples , , WEDNESDAY, ... they,ve identified the contaminant found in the blood-thinner heparin, ... and possibly 19 deaths in the United States. , ... sulfate, but U.S. Food and Drug Administration officials could ...
... Profits before ... Patients, ST. ... their side, International Union of Operating,Engineers Local 49 leaders today at a ... off medical coverage to,several thousand Minnesota seniors., "This is a death ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Metabolic Cardiologist Offers New Hope for Women With Heart Disease 2Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:Park Nicollet to Cut Off Care to Thousands of Minnesota Seniors 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: